Retatrutide: The Triple Agonist — GIP, GLP-1 & Glucagon Receptor Co-Activation

While semaglutide (GLP-1R) and tirzepatide (GLP-1R + GIPR) have dominated metabolic peptide research headlines, a third generation has emerged. Retatrutide (formerly LY3437943, developed by Eli Lilly) is the first triple co-agonist investigated for simultaneous activation of all three incretin and glucagon receptors: GIP, GLP-1, and glucagon. This article covers what makes retatrutide mechanistically distinct and what current research data shows.

Triple Receptor Mechanism

Retatrutide activates three G protein-coupled receptors simultaneously:

• GLP-1R: Glucose-dependent insulin secretion, glucagon suppression, satiety signalling, slowed gastric emptying
• GIPR: Glucose-dependent insulin amplification, possible direct adipose tissue effects, central appetite regulation (additive with GLP-1R)
• Glucagon receptor (GCGR): Hepatic glucose output suppression, increased energy expenditure, potential direct lipolytic effects in adipose tissue

The inclusion of glucagon receptor agonism is the key differentiator. Glucagon classically raises blood glucose (counter-regulatory to insulin), but in the context of simultaneous GLP-1R and GIPR activation, the net metabolic effect is dramatically different: the hepatic glucose-lowering effects of GLP-1R and GIPR activation suppress any glucagon-induced glucose rise, while the GCGR's direct thermogenic and lipolytic effects on adipose tissue add a third dimension of metabolic activity not achievable with dual agonism alone.

Phase 2 Research Data

The TRIUMPH-1 Phase 2 trial (published 2023, NEJM) is the foundational retatrutide dataset. Key findings at 48 weeks:

• 17.5% mean body weight reduction at 12 mg dose (highest among any published incretin compound at the time)
• Dose-dependent response across 1mg, 4mg, 8mg, and 12mg weekly doses
• HbA1c reduction of −2.2% in the diabetes cohort at 12 mg
• Adverse event profile consistent with GLP-1 class effects (nausea, vomiting, primarily early and transient)

Phase 3 trials (TRIUMPH programme) are ongoing. No comparative head-to-head data against tirzepatide is yet published; extrapolated comparisons from Phase 2 data suggest superior weight reduction endpoints but this requires direct RCT confirmation.

Why Retatrutide Research Is Significant

From a research perspective, retatrutide provides the most complete dissection of incretin and glucagon receptor biology achievable with a single compound. Researchers can use retatrutide to probe: What is the incremental contribution of GCGR to thermogenesis above GLP-1R + GIPR? How does triple receptor activation affect hepatic lipid metabolism beyond dual agonism? What is the ceiling of weight reduction achievable via receptor agonism alone?

These questions have implications beyond metabolic research — into fatty liver disease, MASH, cardiovascular risk, and potentially neurodegenerative models where metabolic dysregulation plays a contributing role.

Availability as a Research Compound

Retatrutide is available from Peptiko as a research-grade compound at ≥99% HPLC-MS purity. Given that most research peptide suppliers do not stock this compound — it represents a significant research catalogue advantage for early-stage laboratory investigation.